Correction to: Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

Key Points

• The aim is to address the optimization of cabotegravir plus rilpivirine in HIV treatment.
• Correction of previously published findings regarding cabotegravir and rilpivirine.
• Discussion of implementation strategies in HIV care.
• Identification of evidence gaps in current HIV therapy practices.
• Recommendations for further research on long-acting therapies.